United States Patent 7,189,740: What Claims Cover for Treating Myelodysplastic Syndrome With 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (Scope, Infringement Risk, and US Landscape)

US Patent 7,189,740 centers on a single active-ingredient identity (3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, including salt/solvate/stereoisomers), used in myelodysplastic syndrome (MDS) via dose ranges, oral/capsule/tablet administration, cyclic regimens, patient populations, and optional combination therapy with a broadly enumerated second agent list. The independent claim is a method-of-treatment claim with a daily dose window ~5–50 mg/day. Dependent claims narrow to salt/solvate/enantiopure stereoisomers (R or S), specific MDS subtypes, pre/post transplant timing, treatment-naïve vs previously treated, oral dose forms, and multi-week cyclic schedules (16 or 24 weeks; “21 days on/7 days off” style blocks). Combination claims capture adjunctive regimens with cytokines, growth factors, chemotherapies, immunomodulators, antibiotics, proteasome inhibitors, corticosteroids, and specific named drugs including etanercept, imatinib, anti-TNF-α antibodies, infliximab, G-CSF, GM-CSF, EPO, topotecan, pentoxifylline, ciprofloxacin, irinotecan, vinblastine, dexamethasone, IL2/IL8/IL18, Ara-C (cytarabine), vinorelbine, isotretinoin, 13-cis-retinoic acid, arsenic trioxide.

What patents protect United States Patent 7,189,740’s 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione MDS method?

Answer: The patent protects US method-of-treatment use of the active ingredient for MDS at about 5–50 mg/day, with layered claim coverage for (i) salt/solvate, (ii) enantiopure R or S stereoisomers, (iii) specific MDS phenotypes, (iv) peri-transplant timing, and (v) combination regimens with a second agent.

What is the active-ingredient boundary for claim coverage?

The claims repeatedly anchor infringement risk to the same chemical identity:

Base/identity compound: 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
Permitted variants:
- pharmaceutically acceptable salt (claim 2)
- pharmaceutically acceptable solvate (claim 3)
- stereoisomer (claim 4), including enantiomerically pure R (claim 5) or S (claim 6)
- hydrate solvate (claim 23)

From a freedom-to-operate (FTO) perspective, these dependents matter because they can pull in variants even if a competitor changes the salt or stereochemistry while staying in the same therapeutic use.

How broad is the therapeutic indication boundary?

The independent claim is “a method of treating a myelodysplastic syndrome.” Dependent claim 11 enumerates subtypes:

refractory anemia
refractory anemia with ringed sideroblasts
refractory anemia with excess blasts
refractory anemia with excess blasts in transformation
chronic myelomonocytic leukemia

This creates multiple infringement “hooks” for each subtype if clinical protocols track the claim language.

Which claims in 7,189,740 define the core infringement scenario (dose + route + cyclic use)?

Answer: The core infringement scenario is claim 1 plus operational details from dependent claims. Practically, the daily dose window and the regimen structure are the most operationally meaningful constraints.

What is the daily dose range and how is it supported by dependent claims?

Independent claim 1: administering about 5 to about 50 mg/day of the active ingredient (or acceptable salt/solvate/stereoisomer).

Dependent claim 24 tightens the range framing: about 5–25 mg/day.

Multiple numeric dependents further narrow to standard “design points”:

claim 25: 10 mg/day
claim 26: 15 mg/day
claim 27: 25 mg/day
claim 28: 25 mg every other day to 50 mg every other day

These dependents can matter if a generic, sponsor, or investigator uses fixed doses in studies.

What route and dosage forms are covered?

claim 16: oral administration
claim 17: in the form of a capsule or tablet

If a product is oral and formulated as capsule/tablet, these dependents increase the chance of matching dependent claim elements.

How are cyclic regimens covered?

Several dependent claims are schedule-specific:

claim 18: cyclically
claim 19: once or twice every day for 16 or 24 weeks
claim 20: one cycle = administration of the compound + 1, 2, or 3 weeks of rest
claim 21: number of cycles from one to twelve
claim 22: a highly specific example schedule: 5–25 mg/day for 21 days every 28 days for 16 or 24 weeks
claim 29–31: additional schedule anchoring to “cycle of about 16 weeks” and/or “10 mg/day or 15 mg/day for 21 days out of 28 days blocks,” with rest week components.

For litigation and design-around planning, this is the claim set that maps most directly to how protocols are written and how clinicians titrate schedules.

What patient populations and clinical contexts are captured by dependent claims?

Answer: The claims cover MDS broadly, then add patient and context filters: treatment naïve vs previously treated, peri-transplant timing, and specific MDS subtype language.

How does the patent treat treatment-naïve vs previously treated patients?

claim 14: patient is not previously treated
claim 15: patient previously treated

These are separate dependent claim paths and can broaden coverage if either patient population is used in clinical practice.

What peri-transplant context is covered?

claim 12: administering the compound before, during, or after transplanting
- umbilical cord blood
- placental blood
- peripheral blood stem cell
- hematopoietic stem cell preparation
- bone marrow

This creates a distinct use-case. Even if a regimen differs outside transplant settings, the timing language can re-anchor infringement risk when used in transplant conditioning/adjunct contexts.

What does the combination-therapy coverage in 7,189,740 include?

Answer: Claim 7 adds combination therapy; claim 9 broadly defines acceptable second agents; claim 10 lists specific second agents. This set can preserve infringement even if dose is matched but monotherapy is replaced by combination regimens.

What is the combination claim structure?

claim 7: further comprises administering a therapeutically effective amount of a second active agent
claim 8: the second active agent is capable of improving blood cell production
claim 9: second agent is one of:
- a cytokine
- hematopoietic growth factor
- an anti-cancer agent
- an antibiotic
- a proteasome inhibitor
- an immunosuppressive agent
claim 10: second agent examples include a long enumerated list, with both immunologic agents and oncology drugs.

Which second active agents are enumerated in claim 10?

Claim 10 includes (verbatim list paraphrased into categories for speed):

TNF/immune modulators:
- etanercept
- anti-TNF-α antibodies
- infliximab
TKI / anti-neoplastic:
- imatinib
- topotecan
- irinotecan
- vinblastine
- vinorelbine
Growth factors / erythropoiesis:
- G-CSF
- GM-CSF
- EPO
Immunomodulators / cytokines:
- dexamethasone
- IL2
- IL8
- IL18
Other cytotoxics / antimetabolites:
- Ara-C (cytarabine)
Other anti-cancer / adjunct agents:
- pentoxifylline
- isotretinoin
- 13-cis-retinoic acid
- arsenic trioxide
Antibiotic:
- ciprofloxacin
Plus: pharmacologically active mutants or derivatives

Claim 13 is a specific dependent: second agent is dexamethasone.

What is the practical risk implication of the second-agent list?

Because claim 10 is an enumeration of specific drugs plus the umbrella categories in claim 9, an implemented regimen that combines the core active ingredient with one of these agents can map onto dependent claims even if the primary active ingredient dose remains within the claim window.

How strong is the patent estate for 7,189,740-style coverage: method-of-treatment breadth vs design-around?

Answer: The claim set is structurally strong for enforcing clinical practice parameters because it covers:

active-ingredient variants (salt/solvate/stereoisomer)
numerical dose windows (including fixed dose exemplars)
oral capsule/tablet route and dosage form
cyclic regimen structure (weeks on/off, 21-days-on/28-day blocks)
indication granularity (MDS subtypes)
context filter (peri-transplant timing)
combination therapy with an enumerated drug list

Design-around pressure exists mainly through changing active ingredient identity (not covered), stepping outside the dose ranges (claims use “about,” so exact boundaries need care), and avoiding specific regimen structure that matches dependent claims. Avoiding combination therapy may help against dependent combination claims, but the breadth of claim 1 keeps monotherapy coverage intact.

What is the Orange Book status of 7,189,740 and when does exclusivity expire?

No Orange Book status or FDA exclusivity timing can be stated from the information provided. Without the drug product name, NDA/ANDA/BLA, and Orange Book listing details, exclusivity/expiration cannot be tied to a specific US regulatory record.

When does US Patent 7,189,740 lose exclusivity in the US?

No expiration, patent term adjustment, terminal disclaimer, or co-pending family chronology can be computed from the claim text alone. A definitive “lose exclusivity” date requires the patent’s filing date, priority chain, and any adjustments or disclaimers, which are not present in the prompt.

What patent litigation or Paragraph IV challenges affect 7,189,740?

No litigation docket, settlements, or Paragraph IV filings can be attributed to US Patent 7,189,740 from the information provided. A litigation or certification map requires the court case record or FDA/Orange Book Paragraph IV history tied to a specific NDA/ANDA.

How do the 7,189,740 claims compare with typical MDS method-of-use patent patterns?

Answer: 7,189,740 aligns with common MDS method-of-treatment claim architectures but is unusually operational because it includes:

dose band with “about” plus multiple fixed dose dependents
oral capsule/tablet dependent language
cycle and rest-week definitions (including “21 days out of 28 days”)
explicit coverage for transplant timing
combination therapy with a long enumerated second-agent list

That combination increases enforceability against real-world protocol and regimen documentation.

Claim-by-claim “element map” for enforcement targeting

Below is a practical infringement element checklist distilled from the provided claims.

Claim	Core element(s)	Most likely to be matched in real-world use
1	Treat MDS with active ingredient at ~5–50 mg/day	Baseline monotherapy protocols
2	Active ingredient administered as a pharmaceutically acceptable salt	Product salt form claims
3	Active ingredient administered as a pharmaceutically acceptable solvate	Solvate form variants
4	Active ingredient administered as stereoisomer	Stereochemistry variations
5–6	Enantiopure R or S	If only one enantiomer is marketed
7–10	Combination with second agent that improves blood cell production	Clinician combination regimens
11	MDS subtype enumerations	Subtype-specific studies/labels
12	Before/during/after transplant of blood/stem cell	Transplant-adjunct trials
13	Second agent is dexamethasone	Steroid-containing regimens
14–15	Treatment naïve vs previously treated	Inclusion criteria in trials
16–17	Oral; capsule/tablet	Product form/labeled route
18–22	Cyclic dosing; weeks on/off; 16 or 24 weeks; 21/28 day example	Study schedules and dosing calendars
23	Solvate is hydrate	Formulation-specific variants
24–31	Specific numeric dosing and timing blocks	Fixed-dose regimens and titration endpoints
32–34	Oral 5 or 10 mg capsule/day; free base administration	Formulation and base/route selection

Key Takeaways

US Patent 7,189,740 is a method-of-treatment patent built around one active ingredient identity and variant forms (salt/solvate/stereoisomer).
The most enforceable operational components are the dose ranges (about 5–50 mg/day), oral capsule/tablet, and cyclic regimen structure including 21-days-on/28-day blocks for 16 or 24 weeks.
Coverage expands through dependent claims for MDS subtypes, treatment-naïve vs previously treated, peri-transplant timing, and combination regimens with an enumerated second-agent list that includes TNF modulators, TKIs, growth factors, corticosteroids, cytotoxics, cytokines, and antibiotics.
Any design-around or litigation positioning will turn on whether the competitor’s regimen matches the claim’s dose window, route/form, cycle schedule, and context, and whether their active ingredient remains within the same chemical identity and allowed variants.

FAQs

1) Can a company avoid infringement by switching from free base to a different salt or stereoisomer?
No, the claims explicitly include pharmaceutically acceptable salts, solvates (including hydrates), and stereoisomers, including enantiopure R or S.

2) Do the claims require treatment-naïve patients?
No. The patent includes dependent coverage for both not previously treated and previously treated patients.

3) Are cyclic regimens required for infringement of the independent claim?
No. The independent claim covers MDS treatment at ~5–50 mg/day; cyclic structure appears in dependent claims (18–22, 29–31).

4) Does the patent cover combination therapy only with specific drugs?
The combination limitation is structured broadly in claims 7–9 (categories) and then narrows via claim 10 enumeration and claim 13 (dexamethasone). Use of a listed second agent is an express dependent claim path.

5) Is transplant timing a necessary condition for all claim coverage?
No. Transplant timing is a dependent limitation (claim 12). It expands coverage for transplant-adjunct use but does not replace the independent MDS treatment concept.

References (APA)

No external sources were cited because none were provided in the prompt, and the required bibliographic details (patent number metadata beyond the claim text, prosecution data, Orange Book listings, litigation dockets, and FDA product identifiers) are not included.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	390135	⤷ Start Trial
Australia	2003228508	⤷ Start Trial
Australia	2008202638	⤷ Start Trial
Australia	2011253161	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,189,740

Summary for Patent: 7,189,740